CME on Transplantation is dedicated to online CME conferences, courses and presentations (slides with voice over) on transplantation, given by local and international experts. Its mission is to keep you up-to-date with the most recent developments on transplantation.
Presentation
"Rational Design of Vasculoprotective Compounds and Applications to Clinical Medicine" Dr. Pekka Hayry (biography) English - 2004-06-14 - 66 minutes
Summary : Atherosclerosis is the leading cause of morbidity and mortality in renal transplant patients. More than half of kidney transplant losses are due to the death of the patient with the continued function of the graft (death-censored graft loss) and almost half of these losses are due to vascular events.
In this presentation, Dr. Hayry examines the rationale behind the development of new Vasculoprotective medications. He begins by establishing the need for new therapies and subsequently discusses the pathogenesis of atheromatous plaques, particularly the origin of neo-intimal “smooth muscle cell-like” cells.
The relative merits and short-comings of rodent versus non-human primate models of athermoatous disease are discussed. Dr. Hayry then examines a number of studies pertaining to the newer vasculoprotective drugs, including selective somatostatins, sirolimus and imanitib.
Learning objectives : After viewing this presentation, participants will be able to discuss the:
- Epidemiology and etiology of renal graft loss.
- Predictive value of CADI for predicting renal graft loss.
- Origin of neo-intimal SMC-like cells.
- Relative merits and short-comings of both rodent and primate models of atherosclerosis.
- Distribution and role of somatostatin receptor families.
- Effect of sirolimus in combination with either imanitib or cyclosporine.
Du Toit D, Aavik E, Taskinen E, Myburgh E, Aaltola E, Aimonen M, Aavik S, van Wyk J, Hayry P. Structure of carotid artery in baboon and rat and differences in their response to endothelial denudation angioplasty. Ann Med. 2001 Feb;33(1):63-78.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773-80.
